Statement of Organization, Functions, and Delegations of Authority, 7725 [2021-02093]

Download as PDF Federal Register / Vol. 86, No. 19 / Monday, February 1, 2021 / Notices the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— CE21–004: Research Grants for Preventing Violence and Violence Related Injury. Date: May 25–26, 2021. Time: 8:30 a.m.–5:00 p.m., EDT. Place: Videoconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Mikel Walters, Ph.D., Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639–0913, MWalters@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— CE21–005, The CDC National Centers of Excellence in Youth Violence Prevention (YVPCs): Rigorous Evaluation of Prevention Strategies to Prevent and Reduce Community Rates of Youth Violence. Date: June 22–24, 2021. Time: 8:30 a.m.–5:00 p.m., EDT. Place: Web Conference. Agenda: To review and evaluate grant applications. For Further Information Contact: Mikel Walters, Ph.D., Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639–0913, MWalters@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. [FR Doc. 2021–02051 Filed 1–29–21; 8:45 am] Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. BILLING CODE 4163–18–P [FR Doc. 2021–02054 Filed 1–29–21; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief VerDate Sep<11>2014 16:57 Jan 29, 2021 Jkt 253001 Statement of Organization, Functions, and Delegations of Authority Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 86 FR 6336–6340, dated PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 7725 January 20, 2021) is amended to reflect the Order of Succession for the Centers for Disease Control and Prevention. Section C–C, Order of Succession, is hereby amended as follows: Delete in its entirety Section C–C, Order of Succession, and insert the following: During the absence or disability of the Director, Centers for Disease Control and Prevention (CDC), or in the event of a vacancy in that office, the first official listed below who is available shall act as Director, except that during a planned period of absence, the Director may specify a different order of succession: 1. Principal Deputy Director 2. Chief Medical Officer 3. Deputy Director for Public Health Service and Implementation Science 4. Deputy Director for Infectious Diseases 5. Deputy Director for Public Health Science and Surveillance 6. Deputy Director for Non-Infectious Diseases 7. Director, National Institute for Occupational Safety and Health Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2021–02093 Filed 1–29–21; 8:45 am] BILLING CODE 4160–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and E:\FR\FM\01FEN1.SGM 01FEN1

Agencies

[Federal Register Volume 86, Number 19 (Monday, February 1, 2021)]
[Notices]
[Page 7725]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02093]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Statement of Organization, Functions, and Delegations of 
Authority

    Part C (Centers for Disease Control and Prevention) of the 
Statement of Organization, Functions, and Delegations of Authority of 
the Department of Health and Human Services (45 FR 67772-76, dated 
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as 
amended most recently at 86 FR 6336-6340, dated January 20, 2021) is 
amended to reflect the Order of Succession for the Centers for Disease 
Control and Prevention.
    Section C-C, Order of Succession, is hereby amended as follows:
    Delete in its entirety Section C-C, Order of Succession, and insert 
the following:
    During the absence or disability of the Director, Centers for 
Disease Control and Prevention (CDC), or in the event of a vacancy in 
that office, the first official listed below who is available shall act 
as Director, except that during a planned period of absence, the 
Director may specify a different order of succession:

1. Principal Deputy Director
2. Chief Medical Officer
3. Deputy Director for Public Health Service and Implementation Science
4. Deputy Director for Infectious Diseases
5. Deputy Director for Public Health Science and Surveillance
6. Deputy Director for Non-Infectious Diseases
7. Director, National Institute for Occupational Safety and Health

Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-02093 Filed 1-29-21; 8:45 am]
BILLING CODE 4160-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.